SCHEMBL2670360

SCHEMBL2670360

CC(C)(C)OC(=O)N[C@@]12CCC[C@@]1(F)CNC2

nearest known ligand 0.35

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 1/20 0.34
RORC P51449 1/20 0.31
APLNR P35414 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2670123 1.00 MEN1 (0.34) MEN1MAPK1KMT2ARORCAPLNR
SCHEMBL2670206 0.91 MEN1 (0.35) MEN1MAPK1KMT2AAPLNR
SCHEMBL2670367 0.91 MEN1 (0.35) MEN1MAPK1KMT2AAPLNR
SCHEMBL14139852 0.82 MEN1 (0.35) MEN1MAPK1KMT2ARORC
SCHEMBL2670225 0.82 MEN1 (0.35) MEN1MAPK1KMT2ARORC
SCHEMBL4749107 0.82 MEN1 (0.35) MEN1MAPK1KMT2ARORC
SCHEMBL2670216 0.80 MEN1 (0.34) MEN1MAPK1KMT2A
SCHEMBL14140026 0.80 MEN1 (0.34) MEN1MAPK1KMT2AAPLNR
SCHEMBL4750284 0.80 MEN1 (0.34) MEN1MAPK1KMT2A
SCHEMBL2670327 0.76 MEN1 (0.37) MEN1MAPK1KMT2AAPLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140142096-A1 Fused Substituted Aminopyrrolidine Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-22 US disclosed
US-8618094-B2 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-12-31 US disclosed
EP-2097400-B1 FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-07-03 EP disclosed
US-20130029977-A9 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2013-01-31 US disclosed
EP-2540715-A1 Fused substituted aminopyrrolidine derivative Daiichi Sankyo Company, Limited (JP) 2013-01-02 EP disclosed
US-20120108582-A1 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108582-A1 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885
US-20140142096-A1 Fused Substituted Aminopyrrolidine Derivative NQO2, QDPR, IL4I1 MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885
US-20130029977-A9 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.